Pacer Advisors
HRTX icon

Pacer Advisors’s Heron Therapeutics HRTX Stock Holding History

Pacer Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,465
Closed -$5.13K – 2613
2024
Q2 		$5.13K Buy
+1,465
New +$4.5K ﹤0.01% 3632
2021
Q2 		– Sell
-4,604
Closed -$75K – 1467
2021
Q1 		$75K Sell
4,604
-196
-4% -$3.49K ﹤0.01% 1342
2020
Q4 		$102K Buy
4,800
+794
+20% +$13.8K ﹤0.01% 1363
2020
Q3 		$59K Buy
+4,006
New +$62.5K ﹤0.01% 1297
2018
Q4 		– Sell
-7,053
Closed -$223K – 768
2018
Q3 		$223K Buy
+7,053
New +$263K 0.01% 1011
2018
Q1 		– Sell
-1,600
Closed -$29K – 1078
2017
Q4 		$29K Buy
+1,600
New +$26.1K ﹤0.01% 1071

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors's HRTX Position: Q3 2024 in Review

Pacer Advisors sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 1,465 shares — an estimated $5.13K sold.

Pacer Advisors first reported a position in HRTX in Q4 2017 and held it in 6 quarters. The position peaked at $223K in Q3 2018. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Pacer Advisors reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,465 Heron Therapeutics shares in Q3 2024, an estimated $5.13K.
  • Pacer Advisors first reported a position in Heron Therapeutics in Q4 2017 and held it in 6 quarters.
  • Pacer Advisors's Heron Therapeutics position peaked at $223K in Q3 2018.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.